Ibuprofen
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Ibuprofen: From Pain and Inflammation to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ibuprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID), originally indicated for pain, fever, and inflammation. The TxGNN model predicts it may be effective for Acromesomelic Dysplasia, Hunter-Thompson Type, a rare GDF5-linked skeletal dysplasia, but this direction is currently supported by 0 clinical trials and 0 publications — the prediction is model-driven only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain, fever, and inflammation (NSAID) |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ibuprofen is a non-selective COX-1/COX-2 inhibitor of the propionic acid NSAID class; its efficacy in pain, fever, and inflammation is well established.
Acromesomelic Dysplasia, Hunter-Thompson Type is a rare skeletal dysplasia caused by GDF5 gene mutations, resulting in impaired bone morphogenetic protein (BMP) signaling and disrupted endochondral ossification. While the prostaglandin/COX-2 pathway does participate in the regulation of endochondral ossification, there is no established causal link between COX inhibition and correction of a BMP-signaling defect.
This prediction should be treated as a knowledge-graph embedding similarity result rather than a mechanistically grounded hypothesis — no preclinical, clinical, or literature evidence currently supports applying ibuprofen to this indication.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Ibuprofen currently holds no marketing authorization in New Zealand (0 licenses on file; market status: Not marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is an ultra-rare genetic disorder with no supporting clinical trials, literature, or mechanistic evidence beyond TxGNN's embedding similarity (Evidence Level L5), and ibuprofen has no existing NZ market authorization to build on.
To proceed, the following is needed:
- TFDA/Medsafe package insert data — warnings and contraindications (currently Blocking data gap, DG001)
- Verified mechanism of action data via DrugBank (currently High-severity data gap, DG002)
- Preclinical evidence linking COX inhibition to GDF5/BMP-pathway modulation before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.